We find cancer before it's too late.
xTenure is an intelligence layer and a blood test. We read a lifetime of routine health data to find who is on a cancer trajectory, then screen those people for nine cancers from a single blood draw, potentially years before symptoms appear.
Screening tests do not detect all cancers, and false positive and false negative results can occur. xTenure's test is intended for use alongside, not instead of, screening recommended by your healthcare provider.
South Africa's first AI blood test to screen for nine cancers.
The people we flag give one standard blood draw, processed through an AI-interpreted panel of established tumour markers and assessed against nine cancer types at once.
No scan. No scope. No separate appointment per organ. Analysed in an accredited local laboratory, with results returned through your doctor.
A positive result means further investigation is warranted. It is not a diagnosis, and it does not replace existing screening.
Intelligence infrastructure powering the next generation of predictive oncology
We decide who to test, and we run the test. Both halves, because early detection only works at the scale of a whole population when the two are built together.
LATICEOne programme, in two halves.
Most companies in early detection build one or the other. We build both, because neither works properly on its own.
We model who to test
Our model reads routine health records as a trajectory rather than a set of isolated events, and identifies who is heading somewhere that warrants testing.
This is the enrichment layer. It runs before a single vial is drawn.
Then we take the blood draw
Those people give one standard blood draw, assessed against nine cancer types at once through an AI-interpreted panel of established tumour markers, in an accredited laboratory.
This is the test itself. Results return through a clinician, with a clear next step where a signal is found.
Cancer is still being found too late.
Most cancers are found once they cause symptoms, by which point the disease has often spread. The consequence is measured in survival.
Screening is invasive and organ-by-organ
Each programme targets one organ and needs its own test, equipment and invitation. Many are invasive enough that attendance stays low even where they exist.
Late detection limits treatment
Once cancer spreads, likelihood of survival drops sharply. The earlier it's found, the more can be done.
Late detection carries the heaviest personal cost
Advanced disease brings the longest treatment, the largest bills and the most time lost. What a family absorbs financially and emotionally scales with how late the cancer was found.
Five-year relative survival by stage at diagnosis
SEER, 17 cancer types2Pooled across 17 cancer types. Detection while a cancer is still localised carries roughly six times the five-year survival of detection after distant spread.
Intelligence applied before the test.
Most tests are ordered blind. LATICE reads routine health records to decide who to test first, then escalates only where a signal appears — which is what makes population-level screening affordable.
Identify who to test
LATICE reads longitudinal health data — labs, diagnoses, medications, vitals — as a trajectory rather than isolated events, and flags whose biology is heading somewhere concerning.
Test the right people first
Panels are directed to that higher-risk group rather than administered indiscriminately. The same test performs far better in an enriched population.
Escalate only where warranted
Where a signal appears, LATICE escalates to more specific testing — and only there. Cost lands where it changes outcomes.
Why staged escalation matters. Cancer is rare in any given year, which makes population screening hard: an expensive test for everyone fails economically, and a cheap test for everyone floods the system with false positives. Enriching the tested group first is what makes the arithmetic work.
What is multi-cancer early detection?
Cancer screening was built one organ at a time. Multi-cancer early detection inverts that: one blood draw, many cancers, at once.
Of the nine cancer types xTenure assesses, four have an established screening programme today. The other five — liver, stomach, oesophageal, pancreatic and ovarian — are typically found only once symptoms appear.
One organ, one test, one programme
Screening today is organ-specific. Mammography for breast cancer. Pap or HPV testing for cervical. Colonoscopy or stool tests for colorectal. PSA for prostate, and low-dose CT for lung in some countries.
Each needs its own equipment, staff and eligibility rules — and several are invasive enough that many eligible people simply don't attend.
One blood draw, many cancers, at once
Tumours release measurable material into the blood long before they cause symptoms — proteins, and fragments of tumour DNA. A multi-cancer early detection test measures a panel of these markers from a single ordinary blood draw.
Rather than asking whether one organ is affected, it asks whether a cancer signal is present anywhere. A positive result is not a diagnosis: it directs the next step, usually targeted imaging or specialist referral. These tests complement existing screening, they do not replace it.
Why it matters here. Where organ-by-organ screening infrastructure is costly or unevenly distributed, a single blood draw covering multiple cancers may be the only realistic route to population-scale early detection.
Find what's relevant to you
Select the option that describes you best.
Start a conversation
Health system, insurer, diagnostic partner, research institution, investor — or an individual with a question. We welcome the conversation.
Important safety information
xTenure's test is intended for use in adults at elevated risk of cancer. It does not detect all cancers and should be used in addition to cancer screening recommended by a healthcare provider. The test is intended to detect cancer signals; it is not a diagnostic test.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A result indicating no cancer signal does not rule out cancer. A result indicating a cancer signal requires confirmatory diagnostic evaluation by established procedures, such as imaging, to confirm whether cancer is present. False positive and false negative results do occur.
If cancer is not confirmed on further testing, it may mean cancer is not present, or that testing was insufficient to detect it.
Laboratory and test information
Testing is performed by an accredited South African laboratory partner. Regulatory status and availability may vary. Please contact us for current information on availability in your area.
References
- Sung H, Filho AM, Laversanne M, Ferlay J, Siegel RL, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA Cancer J Clin. 2026;76(4):e70090. doi:10.3322/caac.70090
- Surveillance, Epidemiology, and End Results (SEER) Program, SEER-22 registry data. Age-standardised five-year relative survival by stage at diagnosis, diagnoses 2014–2016, pooled across 17 cancer types.